A Clinical Trial on the Antipsychotic Properties of Cannabidiol
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is
effective in the treatment of acute schizophrenic or schizophreniform psychosis in a
placebo-controlled, randomized double-blind study.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Collaborators:
Coordinating Centre for Clinical Trials Cologne Stanley Medical Research Institute